Candi5V / LimmaTech Biologics - LARVOL DELTA

Assessing the Safety, Immune Response, and Early Efficacy of a Candida Vaccine in Women With Recurrent Vulvovaginal Candidiasis: A Randomized Controlled Study (clinicaltrials.gov) - P1/2 | N=251 | Active, not recruiting | Sponsor: LimmaTech Biologics AG | Recruiting ➔ Active, not recruiting

Enrollment closed • Candidiasis • Vaginitis

Assessing the Safety, Immune Response, and Early Efficacy of a Candida Vaccine in Women With Recurrent Vulvovaginal Candidiasis: A Randomized Controlled Study (clinicaltrials.gov) - P1/2 | N=251 | Active, not recruiting | Sponsor: LimmaTech Biologics AG | Recruiting ➔ Active, not recruiting | Trial completion date: Dec 2026 ➔ Apr 2027 | Trial primary completion date: Dec 2026 ➔ Apr 2027

Enrollment closed • Trial completion date • Trial primary completion date • Candidiasis • Vaginitis

Assessing the Safety, Immune Response, and Early Efficacy of a Candida Vaccine in Women with Recurrent Vulvovaginal Candidiasis: a Randomized Controlled Study (clinicaltrials.gov) - P1/2 | N=251 | Recruiting | Sponsor: LimmaTech Biologics AG | Trial completion date: Dec 2025 ➔ Dec 2026 | Trial primary completion date: Dec 2025 ➔ Dec 2026

Trial completion date • Trial primary completion date • Candidiasis • Vaginitis

Assessing the Safety, Immune Response, and Early Efficacy of a Candida Vaccine in Women With Recurrent Vulvovaginal Candidiasis: A Randomized Controlled Study (clinicaltrials.gov) - P1/2 | N=251 | Recruiting | Sponsor: LimmaTech Biologics AG

New P1/2 trial • Candidiasis • Vaginitis